Back to News
May 12, 2026 12:10 PM

Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts

Shares of Hims & Hers Health Inc (NYSE:HIMS) tanked in early trading on Tuesday, after the company Monday reported disappointing first-quarter results.

Here are the key analyst insights:

JPMorgan analyst Cory Carpenter reiterated an Overweight rating, while cutting the price target from $35 to $33.

Needham analyst Ryan MacDonald maintained a Buy rating, while lifting the price target from $30 to $35.

BTIG analyst David Larsen reaffirmed a Neutral rating on the stock.

Check out other analyst stock ratings.

JPMorgan: Hims & Hers Health reported mixed results, amid "noise" created by the shift from compounded to Novo-branded GLP-1s (glucagon-like peptide-1 receptor agonists), Carpenter said in a note. The company reported revenue of $608 million, representing 4% year-on-year growth, which was "no worse than feared," while strong Wegovy uptake led management to raise their 2026 revenue outlook, he added.

Hims & Hers Health guided to second-quarter revenue of $680-$700 million, representing 27% year-on-year growth, while raising the 2026 revenue outlook from $2.7-$2.9 billion to $2.8-$3.0 billion, the analyst stated. ...